EVIO Labs Massachusetts Announces ISO 17025 Accreditation
Leading cannabis testing company receives accreditation by A2LA
BEND, Ore., Aug. 2, 2018 /CNW/ -- EVIO Inc. ("EVIO" or the "Company"), (OTCQB: EVIO), a leading provider of cannabis testing and scientific research for the regulated cannabis industry in North America, announced today that its Massachusetts laboratory has attained ISO/IEC 17025 accreditation from American Association for Laboratory Accreditation (A2LA). ISO 17025 accreditation is mandatory in Massachusetts for all independent testing laboratories.
ISO/IEC 17025 is the highest recognized quality standard in the world for calibration and testing laboratories. For an organization to be accredited in ISO/IEC 17025, its laboratory is assessed to determine they can consistently produce precise and accurate tests for cannabinoids, pesticides, and contaminants, and have implemented a rigorous quality management system. This also requires personnel to be deemed competent to perform all testing on the scope of accreditation.
"We are very proud of all of the teams' hard work that resulted in this advanced accreditation," said James Kocis, Lab Director of EVIO Labs Massachusetts. "With the state-mandated laboratory regulations, EVIO upholds the high standards of testing and plays a pivotal role in ensuring consumer safety and confidence in the states burgeoning marijuana market."
EVIO Labs Massachusetts is one of only a handful of operating and accredited cannabis testing laboratories in the state and provides testing for the state's medical marijuana market. With the pending roll-out of recreational marijuana, the industry is continuing to ramp up in Massachusetts and EVIO is positioning itself with this milestone to meet the demand of what's to come for state-mandated testing.
About EVIO Inc.
EVIO Inc. is a leading provider of cannabis testing and scientific research for the regulated cannabis industry. The Company's EVIO Labs division operates coast-to-coast providing state-mandated ancillary services to ensure the safety and quality of the nation's cannabis supply. The Company's EVIO Biosciences Division is dedicated to the scientific, medical, and psychosocial exploration of clinical cannabis, cannabinoids, and the endocannabinoid system.
For more information, visit www.eviolabs.com.
About A2LA
A2LA is a non-profit, non-governmental, third-party accreditation body, offering internationally-recognized accreditation services and training to testing and calibration laboratories, inspection bodies, proficiency testing providers, reference material producers and product certifiers.
Safe Harbor Statement
Any statements in this press release that are not statements of historical fact maybe considered to be forward-looking statements. Statements may contain certain forward-looking statements pertaining to future anticipated or projected plans, performance and developments, as well as other statements relating to future operations and results. Words such as "may," "will," "expect," "believe," "anticipate," "estimate," "intends," "goal," "objective," "seek," "attempt," or variations of these or similar words, identify forward-looking statements. These forward-looking statements by their nature are estimates of future results only and involve substantial risks and uncertainties, including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, our ability to complete our product testing and launch our product commercially, the acceptance of our product in the marketplace, the uncertainty of the laws and regulations relating to cannabis, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed from time to time in our reports filed with the Securities and Exchange Commission, available at www.sec.gov or www.eviolabs.com.
CONTACT INFORMATION
Cheryl Kramp
Director of Marketing
EVIO Inc.
888.544.EVIO
[email protected]
SOURCE EVIO Inc.
Share this article